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Abstract
The eﬃcacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) once-daily mono-
therapy in generalized anxiety disorder (GAD) was assessed. This multicentre, double-blind, randomized,
placebo- and active-controlled, phase III trial consisted of a 1- to 4-wk enrolment/wash-out period and a
10-wk (8-wk active treatment, 2-wk post-treatment drug-discontinuation) study period ; 873 patients were
randomized to 50 mg or 150 mg quetiapine XR, 20 mg paroxetine, or placebo. Primary endpoint was
change from randomization at week 8 in Hamilton Rating Scale for Anxiety (HAMA) total score. At
week 8, all active agents produced signiﬁcant improvements in HAMA total and psychic subscale scores
vs. placebo ; HAMA somatic subscale scores were signiﬁcantly reduced only by 150 mg quetiapine XR.
Signiﬁcant separation from placebo (x2.90) in HAMA total score was observed at day 4 for 50 mg
quetiapine XR (x4.43, p<0.001) and 150 mg quetiapine XR (–3.86, p<0.05), but not for paroxetine (–2.69).
Remission (HAMA total score f7) rates at week 8 were signiﬁcantly higher for 150 mg quetiapine XR
(42.6%, p<0.01) and paroxetine (38.8%, p<0.05) vs. placebo (27.2%). The most common adverse events
(AEs) were dry mouth, somnolence, fatigue, dizziness, and headache, for quetiapine XR, and nausea,
headache, dizziness for paroxetine. A lower proportion of patients reported sexual dysfunction with
quetiapine XR [0.9% (50 mg), 1.8% (150 mg)] than with placebo (2.3%) or paroxetine (7.4%). The incidence
of AEs potentially related to extrapyramidal symptoms was : quetiapine XR: 50 mg, 6.8%, 150 mg, 5.0%;
placebo, 1.8%; and paroxetine, 8.4%. Once-daily quetiapine XR is an eﬀective and generally well-tolerated
treatment for patients with GAD, with symptom improvement seen as early as day 4.
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Introduction
Generalized anxiety disorder (GAD) is a prevalent and
chronic illness, having high comorbidity with psychi-
atric disorders, particularly depression, and physical
illness (Nutt et al. 2006). GAD is also associated with
signiﬁcant functional impairment and reduced quality
of life (Ninan, 2001).
Based on clinical studies in the 1970s and 1980s,
conventional antipsychotics were prescribed in
Europe for patients with anxiety disorders (Mendels
et al. 1986; Rickels et al. 1978; Yamamoto et al. 1973),
but at lower doses than for the treatment of
schizophrenia (Mendels et al. 1986). However, in the
USA, conventional antipsychotics were not generally
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used, and were never licensed, for the treatment of
GAD.
Currently, the preferred long-term treatment
options for GAD include selective serotonin re-
uptake inhibitors (SSRIs ; Allgulander et al. 2004)
and serotonin-norepinephrine reuptake inhibitors
(SNRIs ; Gelenberg et al. 2000), with benzodiazepines
(Chouinard, 2004) used in the short term. In Europe,
the calcium channel modulator pregabalin is licensed
for the treatment of GAD, but this agent was not
approved by the US Food and Drug Administration.
Additionally, buspirone is licensed for, and often
prescribed for, GAD, although the eﬃcacy data are
inconsistent (Bandelow et al. 2008).
The search for alternative treatment options is war-
ranted since <40% of patients with GAD achieve re-
covery despite receiving pharmacotherapy with SSRIs,
benzodiazepines or other antidepressants (Rubio &
Lopez-Ibor, 2007). Although there is a paucity of ran-
domized, controlled studies examining treatment
strategies for patients with symptomatic GAD fol-
lowing ﬁrst-line therapy, case-report data suggest
that combination therapy with antidepressants and
benzodiazepines may be eﬀective (Pollack, 2001).
SSRIs and SNRIs have a delayed onset of action
(2–4 wk) (Allgulander et al. 2004 ; Gelenberg et al. 2000;
Rickels et al. 2003), thus short-term adjunct benzodia-
zepine therapy is common when initiating treatment
with these agents. For benzodiazepines, cognitive ef-
fects, rebound anxiety, withdrawal symptoms, and
abuse potential, limit their use in clinical practice
(Chouinard, 2004), while SSRIs and SNRIs are asso-
ciated with sexual dysfunction (Bandelow et al. 2008)
and discontinuation eﬀects (Fava et al. 2007).
Extended-release quetiapine fumarate (quetiapine
XR) oﬀers a potential treatment option for GAD. While
an augmentation study with a small sample size (6/11
patients completed) reported no additional beneﬁt
when quetiapine was added to paroxetine controlled
release (Simon et al. 2008), other studies have reported
positive eﬃcacy results for quetiapine as either
monotherapy or adjunct therapy in patients with GAD
(Adson et al. 2004 ; Galynker et al. 2005 ; Katzman et al.
2008b). This study evaluated the eﬃcacy and toler-
ability of quetiapine XR as once-daily monotherapy
for GAD.
Method
Study design
This was a 10-wk multicentre, double-blind, parallel-
group, placebo- and active- (paroxetine) controlled
study. Paroxetine was included for assay sensi-
tivity. After withdrawal of previous medication dur-
ing a 1- to 4-wk enrolment/wash-out period, eligible
patients entered an 8-wk, randomized, active treat-
ment period, followed by a 2-wk drug-discontinuation
phase.
The study was approved by institutional review
boards for each study site and performed in accord-
ance with the WMA Declaration of Helsinki and
the International Conference on Harmonization/Good
Clinical Practice guidelines. After complete descrip-
tion of the study to the patients, written informed
consent was obtained.
Patients
Eligible patients were male or female (18–65 yr), with
a documented diagnosis of GAD according to DSM-
IV-TR criteria 300.02, as assessed by the Mini-
International Neuropsychiatric Interview.
Patients were required to have a Hamilton Rating
Scale for Anxiety (HAMA) total score o20 with
item 1 (anxious mood) and item 2 (tension) scoreso2
[administered using the Structured Interview Guide
for the HAMA (SIGH-A)], a Montgomery–A˚sberg
Depression Rating Scale (MADRS) total score
f16, and a Clinical Global Impression – Severity of
Illness (CGI-S) score o4 at enrolment and random-
ization.
Exclusion criteria included: diagnosis of any DSM-
IV-TR Axis I disorder other than GAD within 6
months prior to enrolment or any DSM-IV-TR Axis II
disorder that could interfere with the patient’s ability
to participate in the study, a current serious suicidal or
homicidal risk or a MADRS item 10 (suicidality) score
o4 or a suicide attempt during the 6 months prior
to enrolment, substance or alcohol abuse within 6
months prior to enrolment or a clinically signiﬁcant
deviation from reference ranges in clinical laboratory
test results.
Prior to randomization, patients could not have
received: antipsychotic, hypnotic, or antidepressant
medications (including benzodiazepines) within 7 d;
monoamine oxidase inhibitors or mood stabilizers
within 14 d; or ﬂuoxetine within 28 d. Patients were
permitted to receive psychotherapy during the study
period if it had been ongoing for a minimum of 3
months prior to randomization.
Patients were assigned an enrolment code and a
centre-speciﬁc randomization schedule was prepared
from which allocation-numbered drug kits were
packaged and shipped to centres. Patients were ran-
domized to 50 mg or 150 mg quetiapine XR, 20 mg
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paroxetine, or placebo, in a ratio of 1 :1 :1 :1. The ran-
domization list was generated using an internally
developed and validated computer-based random-
ization system.
Packaging was identical for all study treatments ;
placebo tablets for quetiapine XR were identical to
50 mg quetiapine XR. Paroxetine placebo capsules
were identical to 20 mg paroxetine over-encapsulated
tablets. A double-dummy method was used to ensure
that the number of tablets/capsules dispensed was the
same across all treatment groups. Study treatments
were administered orally, once-daily in the evening.
All patients randomized to 50 mg quetiapine XR or
20 mg paroxetine were initiated andmaintained at this
dose. Patients randomized to 150 mg quetiapine XR
started at 50 mg on day 1, and increased to their target
dose of 150 mg (3r50 mg tablets) on day 3. All treat-
ments were discontinued at the end of the study, with
no down-titration of dose.
Concomitant medication
Use of other psychoactive medication was not per-
mitted, except medications for insomnia. The follow-
ing medications were permitted twice weekly up to
week 2, but not on the night before study assessments :
10 mg zolpidem tartrate, 1 g chloral hydrate, 20 mg
zaleplon, 7.5 mg zopiclone. During the randomized
treatment period, centrally acting anticholinergics
were permitted for extrapyramidal symptoms (EPS),
but were not given prophylactically.
Eﬃcacy evaluations
The primary eﬃcacy variable was mean change in
HAMA total score from randomization at week 8.
Additional evaluations included change in HAMA
total score from randomization at day 4 and through-
out, HAMA response (o50% decrease in total score
from randomization) rate and change from random-
ization in HAMA psychic and somatic cluster scores at
day 4 and week 8, and HAMA remission (total score
f7) rate, CGI-S score, proportion of patients with a
CGI-S score of 1 (‘normal, not ill at all ’), proportion of
patients with a CGI-Improvement (CGI-I) score of 1 or
2 (‘very much/much improved’), and change from
randomization in MADRS total score at week 8.
Quality of sleep was assessed at randomization and
week 8 using the Pittsburgh Sleep Quality Index
(PSQI; Buysse et al. 1989).
A post-hoc analysis was conducted to evaluate
the diﬀerence in HAMA total scores between patients
receiving quetiapine XR (pooled doses) with and
without adverse events (AEs) relating to somnolence
(including sedation, lethargy or sluggishness).
Clinical assessments of HAMA, CGI-S, andMADRS
total scores were conducted at enrolment (visit 1,
baseline), day 1 (visit 2, randomization), day 4 (visit 3),
and at weeks 1, 2, 3, 4, 6, and 8 (visits 4–9). CGI-I scores
were determined at visits 3–9. To ensure consistency
throughout the study, each rater administering the
HAMA, MADRS, and CGI scales received training in
conducting these assessments. Certiﬁcation was re-
quired for HAMA and MADRS scale assessment ad-
ministration and raters were approved by the sponsor.
For CGI scales, rater training was required to conduct
these assessments. To reduce scoring variability, it
was also recommended that the same rater conduct all
assessments for a given patient for a speciﬁc scale.
Only qualiﬁed physician raters administered the CGI.
Rater training was performed by United BioSource
Corporation (USA), who independently demonstrated
high levels of inter-rater agreement (k=0.889) in this
study (Kott et al. 2008).
Safety and tolerability assessments
The incidence, severity, and withdrawals because of
AEs were recorded throughout. All AEs and serious
AEs (SAEs), including any ongoing at study end or
discontinuation, were followed up until resolution or
until the investigator decided that no further follow-
up was necessary. Tolerability was assessed through
physical examination and 12-lead electrocardiogram
(ECG) recordings (enrolment and week 8), laboratory
measurements (enrolment, week 4, week 8), and re-
cording of body weight, vital signs, and concomitant
medication (enrolment and all subsequent visits). The
self-administered, 14-item Changes in Sexual Func-
tioning Questionnaire (CSFQ) was completed at ran-
domization and weeks 2, 4, and 8, with separate
versions for males and females (Keller et al. 2006).
Barnes Akathisia Rating Scale (BARS) and Simpson–
Angus Scale (SAS) scores were assessed at random-
ization and weeks 2, 4, 6, and 8. All investigators
performing BARS and SAS ratings received instruc-
tions on how to use these scales and itwas recommend-
ed that the same rater conduct all assessments for a
given patient.
During the 2-wk drug-discontinuation phase, treat-
ment discontinuation signs and symptoms (TDSS)
were measured using a modiﬁed 18-item TDSS scale
(Michelson et al. 2000), which included the additional
AEs vomiting, nausea, and insomnia. Patients com-
pleting the randomized period were asked to rate
discontinuation symptoms using the TDSS scale on
post-treatment days 1, 3, 5, 7, and 14. During the
Quetiapine XR for GAD 307
drug-discontinuation phase patients were encouraged
not to take any medication for anxiety.
Statistical analysis
Intent-to-treat (ITT) populations include all ran-
domized patientswho receivedo1 dose of study drug,
and hado1 post-treatment HAMA; for the analysis of
primary and secondary eﬃcacy variables in this study,
a modiﬁed ITT (MITT) population was used, which
had the additional criteria of a valid baseline HAMA
total score assessment. The drug-discontinuation-
phase (TDSS) population included patients who
completed 8 wk of double-blind treatment and had
baseline (week 8) and o1 post-baseline TDSS assess-
ments. The safety population included patients who
receivedo1 dose of study drug.
The target sample size was 186 patients per treat-
ment group based on an anticipated treatment dif-
ference of 2.75 units from placebo and a standard
deviation (S.D.) of 7.5 for the change in the primary
outcome variable. This sample size provided a 90%
power to show that either quetiapine XR dose was
diﬀerent from placebo. The study was not powered for
a comparison of quetiapine XR vs. paroxetine.
The statistical signiﬁcance of change in HAMA total
scores from randomization at week 8 (primary eﬃcacy
variable) was determined using an analysis of covari-
ance (ANCOVA) model that included terms for base-
line score, treatment, and centre, and used the last
observation carried forward (LOCF) approach for im-
putation of missing data. For the change in HAMA
total scores at each time-point, statistical signiﬁcance
was determined for observed case (OC) data using
the mixed model repeated-measures (MMRM) analy-
sis, which included terms for treatment, baseline
HAMA total score, visit, and treatment/visit inter-
action.
To ensure the overall signiﬁcance level of 0.05 was
preserved for the primary variable, a Bonferroni–
Holm multiple testing procedure (MTP) for groups of
hypotheses was applied to both quetiapine XR treat-
ment groups. Pairwise diﬀerences between the least
squares means (LSMs) for quetiapine XR treatment
groups and placebo were calculated and nominal 95%
conﬁdence intervals (CIs) provided. Comparisons be-
tween paroxetine and placebo were not adjusted for
multiplicity.
All other continuous variables were analysed using
the same ANCOVA model as the primary eﬃcacy
variable, without adjustment for multiplicity. Binary
data were analysed using logistic regression, with
centre included as a random eﬀect. Descriptive
statistics were provided for all variables. Statistical
analyses were two-sided and p values <5% denoted
statistical signiﬁcance.
Results
Patient population
Of 1054 recruited patients, 873 patients met the in-
clusion criteria and were randomized to receive 50 mg
quetiapine XR (n=221), 150 mg quetiapine XR
(n=218), paroxetine (n=217), or placebo (n=217) at
centres in Europe [Bulgaria (76 patients, nine centres),
Czech Republic (113 patients, 10 centres), Denmark (58
patients, four centres), Finland (85 patients, six
centres), France (109 patients, 11 centres), Germany (35
patients, eight centres), Norway (16 patients, four
centres), Romania (48 patients, ﬁve centres), Slovakia
(27 patients, six centres), Spain (19 patients, four
centres), Sweden (39 patients, six centres)], Argentina
(59 patients, 11 centres), Canada (95 patients, 17
centres), Mexico (25 patients, four centres), and South
Africa (69 patients, seven centres) between 18 May
2006 and 15 February 2007. The safety population
comprised 870 patients (three patients did not receive
treatment) and the MITT population included 866
patients (four additional patients were excluded due
to missing/invalid baseline or post-randomization
HAMA total scores).
The demographic and clinical characteristics of
the treatment groups were generally well matched
(Table 1). The proportion of patients completing the
10-wk study and reasons for early withdrawal are
shown in Fig. 1.
Before study entry, 12.1%, 2.8%, and 15.1% of
patients were receiving SSRIs, SNRIs, or benzodiaze-
pines, respectively. The percentage of patients receiv-
ing concomitant sleep medication at any time (weeks
1–8) was: 50 mg quetiapine XR f1.5%, 150 mg
quetiapine XRf3.2%, paroxetinef3.3%, and placebo
f3.8%.
Eﬃcacy
HAMA total scores were signiﬁcantly reduced from
randomization at week 8 for 50 mg quetiapine XR
(x13.95, p<0.05), 150 mg quetiapine XR (x15.96,
p<0.001), and paroxetine (x14.45, p<0.01) vs. placebo
(x12.30) (Table 2, Fig. 2a). The level of signiﬁcance
(determined by MTP analysis) for 50 mg and 150 mg
quetiapine XR vs. placebo was pf0.05 and pf0.025,
respectively.
HAMA total scores were signiﬁcantly reduced with
50 mg quetiapine XR (x4.43, p<0.001) and 150 mg
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quetiapine XR (x3.86, p<0.05) vs. placebo (x2.90) at
day 4, and each subsequent visit (Fig. 2b).
At day 4, HAMA response rates were signiﬁcantly
greater with 50 mg quetiapine XR vs. placebo; at week
8 they were signiﬁcantly greater for all active treat-
ment groups vs. placebo (Table 2). Remission rates at
week 8 were signiﬁcantly greater with 150 mg quetia-
pine XR and paroxetine vs. placebo (Table 2).
The results for other secondary eﬃcacy variables
are shown in Table 2. At week 8, both doses of que-
tiapine XR were associated with signiﬁcant improve-
ments in CGI-S, HAMA psychic cluster, PSQI global,
and MADRS total scores vs. placebo, while signiﬁcant
improvements in HAMA somatic cluster scores and
the proportion of patients with a CGI-I score o2
occurred with 150 mg quetiapine XR.
Post-hoc analysis of HAMA total score and
somnolence
The change in HAMA total score from randomization
at week 8 was similar for patients receiving quetiapine
XR with (x14.90, n=133) or without (x14.95, n=302)
reporting AEs related to somnolence, and signiﬁcantly
greater than for placebo (x12.29, n=217, pf0.01 and
pf0.001, respectively).
Safety and tolerability
10-wk study period (8-wk randomized treatment and
2-wk drug-discontinuation phase)
The overall incidence of AEs reported by patients
(%) was higher in active treatment groups (quetiapine
Table 1. Demographics and baseline characteristics (modiﬁed intent-to-treat population)
Quetiapine XR Quetiapine XR Paroxetine
50 mg 150 mg 20 mg Placebo
(n=219) (n=216) (n=214) (n=217)
Gender, n (%)
Male 70 (32.0) 72 (33.3) 76 (35.5) 82 (37.8)
Female 149 (68.0) 144 (66.7) 138 (64.5) 135 (62.2)
Age, yr
Mean (S.D.) 40.7 (11.6) 42.3 (12.4) 41.6 (11.8) 41.2 (12.8)
Range 18 to 65 18 to 65 19 to 64 18 to 65
Ethnicity, n (%)
White 202 (92.2) 206 (95.4) 205 (95.8) 204 (94.0)
Black 9 (4.1) 9 (4.2) 9 (4.2) 10 (4.6)
Asian 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Other 7 (3.2) 1 (0.5) 0 (0.0) 3 (1.4)
Weight, mean (S.D.) kg 72.1 (16.9) 73.2 (17.3) 74.6 (17.4) 74.6 (17.7)
BMI, mean (S.D.) kg/m2 25.4 (5.2) 25.9 (5.7) 26.1 (5.6) 25.9 (5.2)
Time since ﬁrst onset of anxiety symptoms
Mean (S.D.), yr 12.1 (11.6) 11.4 (11.2) 11.3 (11.1) 11.4 (11.6)
Min to max 1 to 52 1 to 56 1 to 52 1 to 55
Rating scale scores
HAMA total
Mean (S.D.) 26.9 (4.2) 26.6 (4.2) 27.1 (4.0) 27.3 (4.4)
Min to max 20 to 44 14 to 42 20 to 43 20 to 40
MADRS total
Mean (S.D.) 11.5 (3.2) 11.3 (3.1) 11.3 (3.1) 11.5 (3.4)
Min to max 0 to 16 0 to 19 2 to 20 2 to 25
CGI-S
Mean (S.D.) 4.8 (0.7) 4.8 (0.7) 4.8 (0.7) 4.8 (0.7)
Min to max 4 to 6 3 to 6 4 to 7 4 to 6
BMI, Body mass index ; HAMA, Hamilton Rating Scale for Anxiety ; MADRS, Montgomery–A˚sberg Depression Rating Scale ;
CGI-S, Clinical Global Impression – Severity of Illness.
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XR: 50 mg, 70.9%; 150 mg, 76.1%; paroxetine, 72.6%)
compared to placebo (55.8%). The incidence of SAEs
was low in all treatment groups (<1.4%) and none
were considered treatment-related. The percentage
of AEs considered treatment-related was higher in
the quetiapine XR (50 mg, 58.6%; 150 mg, 65.6%) and
paroxetine (58.6%) groups compared to placebo
(34.6%). Discontinuations due to an AE were 11.8%,
16.1%, 7.9%, and 4.1% in the 50-mg and 150-mg
quetiapine XR, paroxetine, and placebo groups, re-
spectively.
8-wk randomized treatment period
Table 3 shows AEs (treatment-related or not) occur-
ring in>5% of patients and AEs potentially related to
sexual dysfunction or EPS.
The most frequent AEs leading to discontinuation
were fatigue (n=7) and somnolence (n=6) (50 mg
quetiapine XR), somnolence (n=11) and fatigue (n=7)
(150 mg quetiapine XR), insomnia (n=5), and dizzi-
ness and fatigue (each n=4) (paroxetine) ; no AE
leading to withdrawal occurred in >1 patient in the
placebo group.
There was a slight improvement in sexual func-
tioning in all treatment groups. The largest improve-
ments (OC) in CSFQ occurred in the quetiapine XR
groups [mean (S.D.) change: 50 mg, 2.3 (7.4), 150 mg,
2.1 (8.1), paroxetine, 0.7 (7.0), placebo, 1.1 (6.6)] and
were similar by gender, with a numerical advantage
for females with quetiapine XR over placebo and
paroxetine.
At week 8, across treatment groups mean decreases
in SAS and BARS were x0.1 to x0.2, and x0.1, re-
spectively. During the randomized treatment period,
centrally acting anticholinergics were used at any
week by f0.5% (placebo), f0.6% [quetiapine XR
(both doses)], andf1.1% (paroxetine) of patients.
Patients screened (N=1054)
Patients screened (N=873)
Screen failures
   Lost to follow-up
   Adverse event
   Death
   Eligibility criteria not fulfilled
   Patient not willing to continue
   Severe non-adherence
   Other
Discontinued 8-wk
randomized period
   Lost to follow-up
   Adverse event
   Development of study-specific
    discontinuation criteria
   Patient not willing to continue
   Lack of therapeutic response 
   Eligibility criteria not fulfilled
   Severe non-adherence
   Other
n=57
n=2
n=25
n=1
n=13
n=9
n=1
n=5
n=1
n=44
n=3
n=16
n=1
n=15
n=4
n=1
n=2
n=2
n=41
n=1
n=8
n=0
n=14
n=13
n=0
n=3
n=2
n=55
n=3
n=32
n=0
n=8
n=1
n=1
n=7
n=3
181
7
3
1
108
60
1
1
Quetiapine XR
50 mga
n=221
Paroxetine
20 mgb
n=217
Placebo
n=217
Quetiapine XR
150 mg
n=218
Completed 8-wk
randomized treatment period
Enrolled in 2-wk TDSS phase
Completed 10-wk study
n=164
n=126
n=115
n=173
n=137
n=119
n=176
n=133
n=126
n=163
n=124
n=113
Fig. 1. Participant ﬂow. a One patient was not treated. b Two patients were not treated. These patients were included in the
discontinued-from-study drug analysis set but were not included in the safety analysis.
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At week 8, there were no clinically relevant mean
changes from baseline in vital signs, ECG, haema-
tology, or clinical laboratory parameters ; however,
higher mean increases in supine pulse and ECG heart
rate were observed with 150 mg quetiapine XR, com-
pared to placebo. Mean changes in glucose and lipid
parameters, and weight, and clinically relevant shifts
in these parameters, are shown in Table 3.
2-wk drug-discontinuation phase
Of the patients completing the 8-wk randomized
treatment period, 76.8% (50 mg quetiapine XR), 76.1%
(150 mg quetiapine XR), 79.2% (paroxetine), and 75.6%
(placebo) enrolled in the 2-wk drug-discontinuation
phase (Fig. 1). Five patients discontinued due to
AEs during the post-treatment period: quetiapine XR
150 mg, n=3 [moderate vertigo, moderate sedation,
and mild depression (same patient), moderate nau-
sea], paroxetine, n=1 (severe back pain), and placebo,
n=1 (severe peritonitis). Table 2 shows mean TDSS
total scores.
The most frequently reported AEs during the drug-
discontinuation phase were insomnia and nausea for
quetiapine XR (both doses), and dizziness and anxiety
for paroxetine (Table 3).
Discussion
This is the ﬁrst randomized, placebo-controlled study
to evaluate the eﬃcacy of quetiapine XR for the treat-
ment of GAD in a large patient population. These re-
sults demonstrate that quetiapine XR (50 mg and
150 mg) is an eﬀective once-daily monotherapy for the
treatment of outpatients with GAD. Although the
study was not powered for a statistical non-inferiority
comparison with paroxetine, changes in eﬃcacy vari-
ables observed with quetiapine XR were of at least the
same magnitude as those for paroxetine. The eﬀect of
quetiapine XR on reducing symptoms of anxiety was
greater than that for placebo and this diﬀerence was
observed as early as day 4. Signiﬁcant separation from
placebo was only seen at week 2 with paroxetine.
At day 4, statistically signiﬁcant diﬀerences from
placebo were seen with quetiapine XR on a number of
outcome variables (HAMA total, psychic, and somatic
scores, HAMA response rate, and CGI-S), but not
with paroxetine. Although currently recommended
as ﬁrst-line for the long-term treatment of GAD,
SSRIs and SNRIs have a 2–4 wk delay in onset of
action (Gelenberg et al. 2000 ; Rickels et al. 2003). To
date, pregabalin and (high-potency) benzodiazepines
are the only other agents to demonstrate anxiolytic
eﬃcacy by week 1 (Montgomery, 2006 ; Rickels et al.
2005). However, as benzodiazepines are associated
with dependency, rebound, and withdrawal issues
(Chouinard, 2004), the early onset of response and
apparent infrequent occurrence of withdrawal symp-
toms observed with quetiapine XR in this study are of
beneﬁt to patients experiencing anxiety symptoms.
The improvement in HAMA total, psychic, and so-
matic scores demonstrate that quetiapine XR is eﬀec-
tive across a wide range of anxiety symptoms. The
beneﬁcial eﬀect of paroxetine in treating somatic
symptoms associated with GAD has been investigated
in several studies (Ball et al. 2005 ; Pollack et al. 2001 ;
Rickels et al. 2003). In the present study, paroxetine did
not signiﬁcantly improve somatic symptoms com-
pared to placebo; however, our study was not de-
signed or powered to test this hypothesis.
In addition to psychic and somatic symptoms, sleep
disturbances are commonly reported by patients with
GAD (Papadimitriou & Linkowski, 2005). Quetiapine
XR was associated with signiﬁcant improvements in
sleep (PSQI global scores) and numerical improve-
ments across a range of PSQI items (including sleep
quality, latency, duration, habitual sleep eﬃcacy, sleep
disturbances, and frequency of sleep medication)
compared to placebo. In the present study, patients
randomized to receive paroxetine did not report sig-
niﬁcant improvements in sleep quality compared to
placebo. In other placebo-controlled studies of parox-
etine in patients with GAD, somnolence (15%) and
insomnia (11%) were the most frequently reported
nervous system AEs (GlaxoSmithKline, 2008) and
these AEs occurred at similar rates in the present
study. As would be expected based on data from pre-
vious clinical trials, both doses of quetiapine XR
(50 mg and 150 mg) were associated with a higher in-
cidence of somnolence (21.8%, 25.2%, respectively)
than insomnia (3.2%, 0.9%, respectively). Identifying
and helping patients with GAD who experience sleep
disturbance are important components of the overall
care for this disorder (Benca, 2001).
In this study, 23.5% of all patients receiving que-
tiapine XR reported somnolence as an AE, with an
early time to onset. While somnolence may have in-
ﬂuenced early improvements in PSQI scores, post-hoc
analysis of the primary endpoint in patients reporting
somnolence-related AEs, suggests that improvement
in anxiety symptoms is related to an anxiolytic eﬀect
rather than somnolence.
Approximately 62% of patients with GAD have co-
morbid depression during their lifetime (Judd et al.
1998). Although patients fulﬁlling the criteria for a
current episode of major depression were excluded
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Table 2. Results for change from randomization at day 4 or week 8 for eﬃcacy variables (MITT population; LOCF), quality of life
sleep measures (PSQI ; MITT population; LOCF), MADRS total scores (safety population ; LOCF), and treatment withdrawal
(TDSS) scores at post-treatment days 1, 7, and 14 (TDSS population; OC)
Quetiapine XR Quetiapine XR Paroxetine
50 mg 150 mg 20 mg Placebo
(n=219) (n=216) (n=214) (n=217)
HAMA total score
Day 4
LSM change x4.43 x3.86 x2.69 x2.90
Estimated diﬀerence vs.
placebo (95% CI)
x1.53
(x2.32 tox0.75)
x0.96
(x1.75 tox0.18)
0.21
(x0.57 to 0.99)
p<0.001 p<0.05 p=0.593
Week 8
LSM change x13.95 x15.96 x14.45 x12.30
Estimated diﬀerence vs.
placebo (95% CI)
x1.65
(x3.12 tox0.18)
x3.66
(x5.13 tox2.19)
x2.15
(x3.63 tox0.68)
p<0.05 p<0.001 p<0.01
HAMA response ratea
Day 4, n (%) 12 (6.4) 7 (3.7) 5 (2.6) 1 (0.5)
p<0.05 p=0.068 p=0.139
Week 8, n (%) 137 (62.6) 153 (70.8) 141 (65.9) 113 (52.1)
p<0.05 p<0.001 p<0.01
HAMA remission rateb
Week 8, n (%) 71 (32.4) 92 (42.6) 83 (38.8) 59 (27.2)
p=0.282 p<0.01 p<0.05
HAMA psychic clusterc
Day 4
LSM change x2.53 x2.38 x1.56 x1.58
Estimated diﬀerence vs.
placebo (95% CI)
x0.95
(x1.42 tox0.48)
x0.80
(x1.26 tox0.33)
0.02
(x0.45 to 0.48)
p<0.001 p<0.001 p=0.937
Week 8
LSM change x7.42 x8.64 x7.70 x6.27
Estimated diﬀerence vs.
placebo (95% CI)
x1.15
(x1.97 tox0.33)
x2.37
(x3.19 tox1.55)
x1.43
(x2.25 tox0.61)
p<0.01 p<0.001 p<0.001
HAMA somatic clusterd
Day 4
LSM change x1.86 x1.45 x1.09 x1.29
Estimated diﬀerence vs.
placebo (95% CI)
x0.57
(x1.03 tox0.11)
x0.16
(x0.63 to 0.30)
0.20
(x0.26 to 0.66)
p<0.05 p=0.482 p=0.395
Week 8
LSM change x6.54 x7.37 x6.74 x6.00
Estimated diﬀerence vs.
placebo (95% CI)
x0.54
(x1.27 to 0.20)
x1.37
(x2.11 tox0.63)
x0.74
(x1.48 tox0.00)
p=0.153 p<0.001 p=0.050
CGI-S
Day 4
LSM change x0.38 x0.35 x0.24 x0.20
Estimated diﬀerence vs.
placebo (95% CI)
x0.18
(x0.28 tox0.07)
x0.15
(x0.26 tox0.04)
0.04
(x0.15 to 0.07)
p<0.01 p<0.01 p=0.498
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Table 2 (cont.)
Quetiapine XR Quetiapine XR Paroxetine
50 mg 150 mg 20 mg Placebo
(n=219) (n=216) (n=214) (n=217)
Week 8
LSM change x1.85 x2.10 x1.95 x1.53
Estimated diﬀerence vs.
placebo (95% CI)
x0.32
(x0.55 tox0.09)
x0.57
(x0.80 tox0.34)
x0.42
(x0.65 tox0.18)
p<0.01 p<0.001 p<0.001
Week 8 : CGI-S score of 1, n (%) 43 (19.6) 49 (22.7) 39 (18.2) 27 (12.4)
CGI-I
Week 8 : CGI-I score of 1 or 2,
n (%)
140 (63.9) 154 (71.3) 140 (65.4) 121 (55.8)
p=0.082 p<0.01 p<0.05
PSQI (Week 8)
Global score, LSM change (95% CI) x4.42
(x4.97 tox3.86)
x4.55
(x5.10 tox4.00)
x3.29
(x3.84 tox2.73)
x2.73
(x3.28 tox2.18)
p<0.001 p<0.001 p=0.099
Sleep quality, mean change (S.D.) x1.0 (0.9) x1.1 (0.9) x0.8 (1.0) x0.5 (0.8)
Sleep latency, mean change (S.D.) x1.0 (1.2) x1.0 (1.2) x0.8 (1.1) x0.5 (1.0)
Sleep duration, mean change (S.D.) x0.8 (1.0) x0.8 (0.9) x0.5 (1.1) x0.5 (0.8)
Habitual sleep eﬃciency, mean change (S.D.) x0.8 (1.3) x0.7 (1.4) x0.6 (1.4) x0.6 (1.4)
Sleep disturbances, mean change (S.D.) x0.6 (0.7) x0.6 (0.7) x0.5 (0.7) x0.3 (0.7)
Frequency of sleep medication,
mean change (S.D.)
x0.5 (1.1) x0.2 (1.1) x0.2 (1.0) x0.2 (1.0)
Daytime dysfunction, mean change (S.D.) x0.4 (0.8) x0.4 (0.9) x0.7 (0.9) x0.5 (0.9)
MADRS total scoree
Week 8
LSM change x4.14 x5.64 x4.63 x2.74
Estimated diﬀerence vs
placebo (95% CI)
x1.40
(x2.39 tox0.41)
x2.90
(x3.89 tox1.90)
x1.89
(x2.89 tox0.90)
p<0.01 p<0.001 p<0.001
TDSS total scoref
(n=126) (n=124) (n=137) (n=133)
Post-treatment day 1 2.3 (3.2) 2.1 (2.0) 1.4 (2.0) 1.5 (1.7)
Post-treatment day 7 2.7 (3.2) 3.2 (3.2) 4.3 (3.9) 2.3 (2.4)
Post-treatment day 14 2.7 (3.2) 2.7 (2.9) 3.7 (3.7) 2.5 (2.8)
MITT, Modiﬁed intent-to-treat ; LOCF, last observation carried forward; PSQI, Pittsburgh Sleep Quality Index ; MADRS,
Montgomery–A˚sberg Depression Rating Scale ; TDSS, treatment discontinuation signs and symptoms; OC, observed case ;
HAMA, Hamilton Rating Scale for Anxiety ; CI, conﬁdence interval ; LSM, least squares means ; CGI-S, Clinical Global
Impression – Severity of Illness ; CGI-I, Clinical Global Impression – Improvement.
All p values vs. placebo.
ao50% reduction in HAMA total score from baseline.
b HAMA total scoref7.
c Consisting of the following items : anxious mood, tension, fears, insomnia, intellectual changes, depressed mood, and
behaviour symptoms.
d Consisting of the following items : muscular, sensory and cardiovascular, respiratory, gastrointestinal, genitourinary, and
autonomic system disturbances.
e Safety population.
f Observed cases ; drug-discontinuation phase population.
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from this study, improvements in MADRS total scores
indicate that quetiapine XR monotherapy reduces de-
pressive symptoms in non-depressed patients with
GAD compared to placebo; paroxetine also improved
MADRS total scores.
AEs were reported by patients in all treatment
groups. The pattern of common AEs, incidence of AEs
of special interest, and changes in clinical laboratory
results and vital signs for the quetiapine XR treatment
groups were consistent with the known pharmaco-
logical and safety proﬁle of quetiapine (Arvanitis et al.
1997 ; Timdahl et al. 2007). In this study, the proportion
of patients reporting AEs related to sexual dysfunction
was higher for paroxetine than for either quetiapine
XR dose or placebo.
The incidence of spontaneously reported EPS-
related AEs with quetiapine XR was low and these
were generally mild to moderate in intensity. These
results were conﬁrmed by the assessment of parkin-
sonian and akathisia symptoms using SAS and BARS
scores, which indicated a similar magnitude of change
in the quetiapine XR (50 mg, 150 mg) and placebo
treatment groups. While atypical antipsychotics are
associated with a lower risk for EPS than conventional
antipsychotics, it is important that patients are moni-
tored for the emergence of events potentially related
to EPS (Casey, 2006). EPS-like symptoms have also
been reported with SSRI and SNRI treatments (Leo,
1996) and in the present study paroxetine was as-
sociated with a higher incidence of EPS-related AEs
than either quetiapine XR or placebo.
Laboratory data revealed no clinically relevant
changes in glucose, total cholesterol, high-density
lipoprotein (HDL)-cholesterol, low-density lipoprotein
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Fig. 2. Change in HAMA total score from randomization. (a) At day 4 and week 8 (MITT population ; LOCF) ; * p<0.05,
** p<0.01, *** p<0.001 vs. placebo ; # p value adjusted for multiplicity. (b) Over time (MITT population ; OC, MMRM);
* p<0.05, ** p<0.01, *** p<0.001 vs. placebo.
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(LDL)-cholesterol, or triglycerides in patients receiv-
ing quetiapine XR; however, large variability in these
data limits interpretation. Numerical increases in glu-
cose levels and triglycerides were seen in this trial for
quetiapine XR, compared to placebo. Elevations of
these parameters are consistent with the known phar-
macological proﬁle of quetiapine in other disorders.
Patients in both quetiapine XR groups experienced
an increase in mean weight, and a higher percentage
of patients reported weight gain o7% during the
study, compared to placebo-treated patients. The
mean change in body weight in this study (0.6–1.1 kg)
is similar to that reported in two acute studies of que-
tiapine XR in patients with schizophrenia (Ganesan
et al. 2008 ; Kahn et al. 2007). Longer-term studies are
needed to evaluate these metabolic eﬀects during
maintenance treatment for GAD. Weight increases
have also been observed with SSRIs and with other
antidepressants (Fava, 2000). Paroxetine has been
shown to cause weight gain (Marks et al. 2008). In the
present study, mean increase in weight with parox-
etine was similar to that seen with placebo, although
the proportion of patients with weight gaino7% was
greater than in the placebo group.
The present study was designed to evaluate que-
tiapine XR in the acute treatment of GAD and there-
fore lasted for 10 wk, including 8 wk of active
treatment. The changes in laboratory parameters and
weight in this study are consistent with observations
in short-term monotherapy studies from the quetia-
pine XR clinical programme in patients with major
depressive disorder (Cutler et al. 2009; Weisler et al.
2009). Publication of results from a completed main-
tenance study investigating quetiapine XR in patients
with GAD is awaited.
Paroxetine was administered at a dose of 20 mg in
this study; however, higher doses (up to 60 mg) have
been used in clinical trials of GAD. Nonetheless, in one
ﬁxed-dose study, 40 mg paroxetine did not show sig-
niﬁcantly greater improvement than 20 mg for the
treatment of GAD (Rickels et al. 2003). The 20-mg dose
utilized in our study is in accordance with the parox-
etine prescribing information. Although it is usually
recommended to dose paroxetine in the morning, this
agent was administered in the evening throughout the
study to maintain blinding.
Lower daily doses were possible in patients with
GAD compared the recommended dose range for
patients with schizophrenia (400–800 mg) and a once-
daily, evening dosing regimen could be utilized with
the XR formulation of quetiapine.
Due to the exclusion of patients with comorbid de-
pression, which is standard procedure in clinical trials
of anxiety disorders, the patient population in our
study may not be truly representative of patients with
GAD in clinical practice. Notably, quetiapine is eﬀec-
tive in, and is approved for, the treatment of bipolar
depression (Calabrese et al. 2005 ; Thase et al. 2006) and
quetiapine XR has proven eﬃcacy in treating de-
pressive symptoms (Bauer et al. 2009 ; Cutler et al.
2009 ; Weisler et al. 2009). A speciﬁc measure of dis-
ability was not utilized in the present study as such
scales are often not sensitive to acute changes. It was
therefore not possible to formally assess the baseline
level of impairment or changes in functioning that
may have occurred following treatment. However,
quetiapine XR monotherapy was signiﬁcantly more
eﬀective in maintaining improvements in Sheehan
Disability Scale scores compared to placebo in a time-
to-event (f52 wk) multicentre, randomized-with-
drawal, double-blind, long-term study (Katzman et al.
2008a) ; full publication of these results is awaited.
Although the precise mechanism of action is
unknown, the anxiolytic eﬃcacy demonstrated by
quetiapine may be due to its actions on the dopamine,
serotonin, and norepinephrine neurotransmitter sys-
tems, or a combination of these eﬀects. Both quetiapine
and norquetiapine (active human metabolite) have
moderate to high aﬃnity for dopamine D2 and sero-
tonin 5-HT2A receptors and norquetiapine is a potent
inhibitor of the norepinephrine transporter (Goldstein
et al. 2008 ; Jensen et al. 2008). As most drugs that are
eﬀective in the treatment of anxiety disorders enhance
serotonergic and/or noradrenergic neurotransmis-
sion, it may be assumed that the anxiolytic eﬀects of
quetiapine are achieved via antagonism at serotonin
5-HT2A receptors by norquetiapine and quetiapine,
and/or inhibition of norepinephrine reuptake by nor-
quetiapine. Additionally, preclinical studies have
shown that antagonism at D2 receptors plays a role in
the anxiolytic eﬀect of quetiapine in rodents (Maciag
et al. 2007).
GAD is a serious illness and many patients do not
recover following adequate treatment with cur-
rently available pharmacotherapies. Moreover, many
(>40%) patients with GAD experience residual an-
xiety symptoms 6–12 yr after diagnosis (Tyrer &
Baldwin, 2006 ; Yonkers et al. 2000). In general, treat-
ment guidelines do not recommend the use of con-
ventional antipsychotics for patients with GAD due to
the associated risk of EPS; however, atypical anti-
psychotics may have utility in this patient population
(Bandelow et al. 2008; IPAP, 2008). Nonetheless, when
deciding upon a particular pharmacotherapy, it is
important that any beneﬁts associated with treatment
are carefully measured against potential risks, taking
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Table 3. Most frequently reported adverse events (AEs) (with an incidence of>5% in any group) during the 8-wk
randomized treatment period and during the drug-discontinuation phase, AEs of special interest (sexual dysfunction and
extrapyramidal symptoms) occurring during the 8-wk randomized treatment period, and changes in clinical laboratory
parameters and body weight from baseline end of treatment (safety population)
Quetiapine XR Quetiapine XR Paroxetine
50 mg 150 mg 20 mg Placebo
(n=220) (n=218) (n=215) (n=217)
Randomized treatment period, MedDRA preferred term, n (%)
Dry mouth 35 (15.9) 56 (25.7) 21 (9.8) 13 (6.0)
Somnolencea 48 (21.8) 55 (25.2) 24 (11.2) 10 (4.6)
Fatigue 33 (15.0) 36 (16.5) 20 (9.3) 8 (3.7)
Dizziness 26 (11.8) 34 (15.6) 29 (13.5) 13 (6.0)
Headache 36 (16.4) 27 (12.4) 37 (17.2) 39 (18.0)
Sedation 14 (6.4) 18 (8.3) 5 (2.3) 1 (0.5)
Nausea 17 (7.7) 14 (6.4) 44 (20.5) 16 (7.4)
Constipation 10 (4.5) 13 (6.0) 6 (2.8) 3 (1.4)
Diarrhoea 7 (3.2) 8 (3.7) 12 (5.6) 10 (4.6)
Nasopharyngitis 7 (3.2) 5 (2.3) 13 (6.0) 8 (3.7)
Insomnia 7 (3.2) 2 (0.9) 20 (9.3) 9 (4.1)
Drug-discontinuation phase, MedDRA preferred term, n (%)
Insomnia 10 (4.5) 17 (7.8) 9 (4.2) 5 (2.3)
Nausea 8 (3.6) 12 (5.5) 9 (4.2) 4 (1.8)
Anxiety 3 (1.4) 3 (1.4) 11 (5.1) 1 (0.5)
Dizziness 7 (3.2) 3 (1.4) 22 (10.2) 3 (1.4)
AEs of special interest, n (%)
Sexual dysfunctionb 2 (0.9) 4 (1.8) 16 (7.4) 5 (2.3)
Extrapyramidal symptomsc 15 (6.8) 11 (5.0) 18 (8.4) 4 (1.8)
Laboratory parameters
Glucose (mg/dl)d
Mean (S.D.) baseline 93.6 (11.1) 94.3 (13.3) 93.3 (12.4) 94.6 (11.7)
Mean (S.D.) change x0.9 (16.6) 0.9 (12.7) 1.0 (12.2) 0.7 (11.4)
Patients with fasting glucose
o126 mg/dL at end of treatment, n (%)
2 (1.2) 1 (0.6) 3 (1.9) 3 (1.8)
Total cholesterol (mg/dl)d
Mean (S.D.) baseline 200.6 (43.6) 201.9 (46.4) 202.7 (44.2) 199.3 (48.1)
Mean (S.D.) change x0.4 (27.1) 1.1 (31.7) 0.9 (26.9) 0.8 (27.1)
Patients with fasting total cholesterol
o240 mg/dl at end of treatment, n (%)
9 (7.6) 11 (8.5) 14 (11.4) 7 (5.3)
LDL-cholesterol (mg/dl)d
Mean (S.D.) baseline 118.0 (37.0) 120.0 (40.9) 121.4 (38.7) 116.9 (39.2)
Mean (S.D.) change 0.3 (24.6) x0.7 (26.1) 1.1 (22.4) 1.6 (24.1)
Patients with fasting LDL-cholesterol
o160 mg/dl at end of treatment, n (%)
7 (5.6) 9 (6.7) 14 (10.6) 8 (5.8)
HDL-cholesterol (mg/dl)d
Mean (S.D.) baseline 58.2 (17.2) 58.0 (15.7) 57.8 (17.2) 57.7 (17.5)
Mean (S.D.) change x0.3 (9.6) x2.0 (9.4) x0.1 (9.7) 0.7 (8.6)
Patients with fasting HDL-cholesterol
f40 mg/dl at end of treatment, n (%)
6 (4.7) 8 (5.9) 3 (2.2) 12 (8.6)
Triglycerides (mg/dl)d
Mean (S.D.) baseline 123.8 (74.0) 120.6 (71.3) 118.1 (64.7) 127.4 (86.2)
Mean (S.D.) change x3.0 (56.8) 19.7 (67.5) x0.2 (54.1) x8.3 (64.1)
Patients with fasting triglycerides
o200 mg/dl at end of treatment, n (%)
7 (5.5) 18 (13.6) 8 (5.8) 6 (4.3)
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into account the complete tolerability proﬁle for a
given agent as well as individual patient factors. As the
present study is short term, additional relapse pre-
vention studies are necessary to establish if the bene-
ﬁts of quetiapine XR in GAD are maintained over the
longer term and to assess the tolerability proﬁle in this
setting.
In summary, results reported here show that
quetiapine XR once-daily monotherapy is an eﬀective
and generally well-tolerated treatment for patients
with GAD, with symptom improvement seen as early
as day 4, and a positive inﬂuence on sleep dis-
turbances. Thus, quetiapine XR may oﬀer an alterna-
tive treatment option for patients with anxiety
symptoms.
Appendix : Investigators involved in the study
Argentina : Ricardo Corral (Buenos Aires), Carlos
Finkelsztein (Buenos Aires), Christian Lupo (Rosario),
Miguel Ma´rquez (Buenos Aires), Pedro Gargoloﬀ
(Buenos Aires), Julio Herrera (Mendoza), Roxana
Galeno (Mendoza), Gerardo Garcia Bonetto
(Co´rdoba), Alberto Bertoldi (Buenos Aires), Carlos
Morra (Co´rdoba), Daniel Mosca (Buenos Aires) ;
Bulgaria : Lubomir Jivkov (Soﬁa), Temenuzhka
Mateva (Ruse), Stefan Todorov (Varna), Rinaldo
Shishkov (Varna), Damjan Getev (Kardjali), Ognian
Tanchev (Soﬁa), Emilia Veleva (Soﬁa), Georgi Parchev
(Veliko Tarnova), Nadia Ivanova (Vratza) ; Canada :
Guy Chouinard (Quebec, QC), Richard Bergeron
(Gatineau, QC), Sanjay Siddhartha (Miramichi, NB),
Raymond Matte (Sherbrooke, QC), Angelo Fallu
(Sherbrooke, QC), Serge Lessard (Orleans, ON),
Sunny Johnson (Mississauga, ON), Paul Latimer
(Kelownanm BC), Ranjith Chandrasena (Chatham,
ON), Muhammad Sayeed (Corner Brook, NL), Brian
Ticoll (Markham, ON), Arun Ravindran (Toronto,
ON), Mysore Renuka-Prasad (Saskatoon, SK), Javed
Ali (Sydney, NS), Arthur David Kantor (Toronto, ON),
Eric Giguere (Montreal, QC), Jacques Bradwejn
(Ottawa, ON), Kevin Kjernisted (Vancouver, BC),
Rama Prayaga (Brantford, ON), Anil Joseph,
(Sudbury, ON); Czech Republic : Zdenek Solle
(Praha), Erik Herman (Praha), Eva Soukupova (Plzen),
Michaela Klabusayova (Brno), Ilona Divacka (Praha),
Jaroslav Lestina (Praha), Jiri Pisvejc (Litomerice), Jiri
Bilik (Olomouc), Juraj Rektor (Prerov), Jiri Rozkos
(Prostejov) ; Denmark : Jesper Søgaard (København),
Stig Rasmussen (Hillerød), Bjarne Bahr (København),
Bjarne Nielsen (Hellerup), Kirsten Behnke
(Frederiksberg), Erik Kjærsgaard Nielsen (Haderslev),
Eivind Knutsen (A˚rhus) ; Finland : Antti Ahokas
(Helsinki), Anna Savela (Helsinki), Raili Kansanen
(Helsinki), Riitta Jokinen (Turku), Jukka Penttinen
Table 3 (cont.)
Quetiapine XR Quetiapine XR Paroxetine
50 mg 150 mg 20 mg Placebo
(n=220) (n=218) (n=215) (n=217)
Prolactin (ng/ml)e
Mean (S.D.) baseline 10.0 (8.8) 10.1 (9.9) 9.5 (5.8) 10.7 (9.8)
Mean (S.D.) change x0.4 (5.9) 0.0 (10.7) 2.3 (17.1) x1.0 (10. 7)
Weight (kg), mean (S.D.) change 0.6 (2.3) 1.1 (2.2) 0.0 (2.2) 0.1 (2.8)
Patients with ao7% increase in body
weight at end of treatment, n (%)
10 (4.6) 15 (6.9) 10 (4.7) 5 (2.3)
MedDRA, Medical Dictionary for Regulatory Activities ; LDL, low-density lipoprotein ; HDL, high-density lipoprotein.
a The median times to ﬁrst onset of somnolence were 2.0, 4.5, and 4.0 d for the quetiapine XR, paroxetine, and placebo groups,
respectively.
bMedDRA preferred terms: anorgasmia, ejaculation disorder, libido decreased, loss of libido, orgasm abnormal, sexual
dysfunction, spontaneous penile erection ; three of these AEswere severe in intensity [150 mg quetiapine XR, n=1 (loss of libido) ;
paroxetine, n=2 (one each of loss of libido and sexual dysfunction)].
c MedDRA preferred terms: akathisia, restlessness, tremor, extrapyramidal disorder, bradykinesia, dyskinesia, hypertonia,
muscle rigidity, psychomotor hyperactivity ; two of these AEs were severe in intensity, tremor in the 150 mg quetiapine XR
group (n=1) and dyskinesia in the paroxetine group (n=1).
d Fasting documented by patient report of at least 8 h since last meal before blood draw for both baseline and post-baseline
sampling.
e Normal prolactin range (double antibody radioimmunoassay) : 2–20 ng/ml (males) ; 2–29 ng/ml (females).
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(Salo), Juhani Aer (Ja¨rvenpa¨a¨) ; France : Joe¨l
Gailledreau (Elancourt), Eric Neuman (Le Pecq),
Fre´de´ric Chapelle (Toulouse), Christian Gaussares
(Arcahon), Joe¨l Pon (Toulouse), Mocrane Abbar
(Nimes), Pierre Le Goubey (Cherbourg), Paule Khalifa
(Toulouse), Jean Audet (Angouleme), Bertrand
Baranovsky (Rennes), Christophe Dufour (La Valette
du Var) ; Germany : Borwin Bandelow (Go¨ttingen),
Bernd Gestewitz (Bad Saarow), Alexander Schulze
(Berlin), Klaus-Christian Steinwachs (Nu¨rnberg),
Serena Scarel (Unterhaching), Eugen Schlegel (Siegen),
Andrej Pauls (Mu¨nchen), Ansgar Frieling (Hamburg),
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